title: Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy.
abstract: BACKGROUND
  The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated.
  
  
  METHODS
  To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis C during 1999-2004. The patients were from 12 health care centers throughout the country, and they were followed up for a mean (+/- SD) period of 14+/-15.8 months. Biochemical liver tests were performed, and HCV RNA levels were monitored.
  
  
  RESULTS
  A total of 146 patients (68%) had symptomatic disease. The most common risk factors for acquiring hepatitis C that were reported were intravenous drug use and medical procedures. The proportion of subjects with spontaneous resolution of infection was 36%. The average timespan from disease onset to HCV RNA clearance was 71 days (range, 27-173 days). In fact, 58 (80%) of 73 patients with self-limiting hepatitis experienced HCV RNA clearance within 3 months of disease onset. Multiple logistic regression analyses showed that none of the variables considered (including asymptomatic disease) were associated with increased risk of developing chronic hepatitis C.
  
  
  CONCLUSIONS
  These findings underscore the importance of medical procedures as risk factors in the current spread of HCV infection in Italy. Because nearly all patients with acute, self-limiting hepatitis C--both symptomatic and asymptomatic--have spontaneous viral clearance within 3 months of disease onset, it seems reasonable to start treatment after this time period ends to avoid costly and useless treatment.
authors.affiliation: Clinic of Infectious Diseases, University of Bari, Bari, Italy. t.santantonio@clininf.uniba.it
authors.forename: T
authors.initials: T
authors.lastname: Santantonio
authors.forename: E
authors.initials: E
authors.lastname: Medda
authors.forename: C
authors.initials: C
authors.lastname: Ferrari
authors.forename: P
authors.initials: P
authors.lastname: Fabris
authors.forename: G
authors.initials: G
authors.lastname: Cariti
authors.forename: M
authors.initials: M
authors.lastname: Massari
authors.forename: S
authors.initials: S
authors.lastname: Babudieri
authors.forename: M
authors.initials: M
authors.lastname: Toti
authors.forename: R
authors.initials: R
authors.lastname: Francavilla
authors.forename: F
authors.initials: F
authors.lastname: Ancarani
authors.forename: G
authors.initials: G
authors.lastname: Antonucci
authors.forename: G
authors.initials: G
authors.lastname: Scotto
authors.forename: V
authors.initials: V
authors.lastname: Di Marco
authors.forename: G
authors.initials: G
authors.lastname: Pastore
authors.forename: T
authors.initials: T
authors.lastname: Stroffolini
mesh_terms: D000208:Acute Disease; D000328:Adult; D017714:Community-Acquired Infections / Q000453:epidemiology* / Q000821:virology; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification*; D006526:Hepatitis C / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012307:Risk Factors